TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04633291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel swelling media
Description: Intermittent catheterization through the urethra draining the bladder, performed by a trained nurse.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator swelling media
Description: Intermittent catheterization through the urethra draining the bladder, performed by a trained nurse.
Study: NCT00851864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Description: LMWH (tinzaparin-Innohep, Leo Pharma A/S) 175 anti-factor Xa units per kilogram of body weight sub-cutaneously once daily.~Treatment will be done for the duration of the pregnancy.
Study: NCT01858025

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pencil Beam scanning Radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-C
Study: NCT02104167

Intervention type: DEVICE
Intervention: ROIC interbody cage with VerteBRIDGE plating
Study: NCT01030354

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Herbalife Meal Replacements
Description: Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Herbalife Meal Replacements
Description: Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Herbalife Meal Replacements
Description: Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Herbalife Meal Replacements
Description: Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass.
Study: NCT02143934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pills, appearance identical to Primaquine tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chloroquine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artemether Lumefantrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether Lumefantrine
Study: NCT03126123

Intervention type: PROCEDURE
Group type: OTHER
Intervention: acetic acid test
Description: Patients will receive acetic acid on the mucosa of the anal canal before the surgical procedure
Study: NCT01068587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MET/VEGFR2 inhibitor Foretinib
Description: PhaseI and Phase II Arm A:~Foretinib PO daily dosing starting cycle 1 day 15 and erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib hydrochloride
Description: erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib hydrochloride
Description: erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Tumour markers alone cannot be used to assess objective tumour response. If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Tumour markers alone cannot be used to assess objective tumour response. If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response
Study: NCT04571385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP30663
Description: Administer by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP30663
Description: Administer by intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to AP30663.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to AP30663.
Study: NCT00932386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hcl infusion
Description: 0.5mcg/kg/hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 0.9% normal saline infusing
Study: NCT04145388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online cancer risk assessment
Description: Electronic surveys to collect family cancer history information.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online cancer risk assessment
Description: Electronic surveys to collect family cancer history information.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Family cancer history captured by provider during a clinical encounter
Study: NCT01387945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBPM+website+patient navigator
Description: In addition to home blood pressure monitor, patient receives access to BP web portal and trained patient navigator.
Study: NCT00143468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mechanical ventilation
Description: measurement of specific lung elastance during mechanical ventilation
Study: NCT04156399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: All subjects will receive a standardized 18 needle acupuncture protocol.
Study: NCT00687245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole magnesium
Description: capsules, oral, qd, one day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole magnesium
Description: capsules, oral, qd, one day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole magnesium
Description: capsules, oral, qd, one day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole magnesium
Description: capsules, oral, qd, one day
Study: NCT03163706

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Modified Stroop effect
Description: to assess whether attention deficits and executive functions in patients with schizophrenia are general (semantic and response conflict) or specific (semantic or response conflict).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Stroop effect
Description: to assess whether attention deficits and executive functions in patients with schizophrenia are general (semantic and response conflict) or specific (semantic or response conflict).
Study: NCT04531306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio® Tape
Description: Fascial taping technique for myofascial trigger points on the iliotibial band

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio® Tape
Description: Fascial taping technique for myofascial trigger points on the iliotibial band

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio® Tape
Description: Fascial taping technique for myofascial trigger points on the iliotibial band

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio® Tape
Description: Fascial taping technique for myofascial trigger points on the iliotibial band
Study: NCT01339299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant luteinizing hormone (r-LH)
Description: administration of r-LH 150 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human chorionic gonadotropin (r-hCG)
Description: administration of r-hCG 25 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)
Study: NCT02414126

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effect of CPAP on respiratory work and cardiac function indices during wakefulness
Description: Comparison of three periods of 3 hours~1. st period: Spontaneous breathing for 10 minutes~2. nd period: CPAP for 10 minutes~3. rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~* oesogastric pressures~* air flow~* gas exchange~* right and left cardiac function~Patients \> 6 years old will assess their dyspnea on a visual analogue scale

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effect of CPAP on respiratory work and cardiac function indices during wakefulness
Description: Comparison of three periods of 3 hours~1. st period: Spontaneous breathing for 10 minutes~2. nd period: CPAP for 10 minutes~3. rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~* oesogastric pressures~* air flow~* gas exchange~* right and left cardiac function~Patients \> 6 years old will assess their dyspnea on a visual analogue scale

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effect of CPAP on respiratory work and cardiac function indices during wakefulness
Description: Comparison of three periods of 3 hours~1. st period: Spontaneous breathing for 10 minutes~2. nd period: CPAP for 10 minutes~3. rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~* oesogastric pressures~* air flow~* gas exchange~* right and left cardiac function~Patients \> 6 years old will assess their dyspnea on a visual analogue scale

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Study: NCT03624387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Painting Sessions
Description: During the GIA painting session, each participant will be given a white canvas, four brushes and four different colors of painting.Their only instruction will be to cover the white color of the canvas. At the end of each session, the performance of the participants will be evaluated based on their neuropsychological conditions before and after Geriatric Inclusive Art session.
Study: NCT02197442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Study: NCT02946489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581a
Description: CI-581a will be administered in wk2 and potentially in wk 3 or 4.
Study: NCT01950156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant
Description: Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A\*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant.
Study: NCT00073008

Intervention type: DRUG
Group type: OTHER
Intervention: GW572016 (lapatinib)
Description: tyrosine kinase inhibitor
Study: NCT02155322

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2b
Description: 6 μg/kg, weekly dosing, subcutaneous administration, Induction Phase - first 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2b
Description: 3 μg/kg SC once weekly for a 42-week maintenance phase (for a total treatment of up to approximately 1 year)
Study: NCT01905592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niraparib
Description: 300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's choice
Description: Choice of 4 standard of care metastatic breast cancer chemotherapies, until progression or unacceptable toxicity develops
Study: NCT00621517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Partipants will receive 150 mg bupropion per night

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule nightly for six weeks
Study: NCT04564105

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: simulation education
Description: Intubation protocol will be trained by simulation exercise.
Study: NCT03395847

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04475770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Sustained Natural Apophyseal Glides (SNAGS)
Description: Manual therapists use treatment modalities that include passive techniques such as mobilization and manipulation. Mobilization with movement (MWM) developed by Mulligan involves applying a sustained transverse glide to the spinous process of a vertebra while actively or passively performing. These techniques have gained the name Sustained Natural Apophyseal Glides (SNAGS) as it is maintained at the pain-free range and follows the plane of the apophyseal joints under treatment.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Sustained Natural Apophyseal Glides (SNAGS)
Description: The participants in the Sham SNAGs group will be positioned same as the SNAG group. Mulligan belt will be used, which included the patient's waist and physiotherapist's hip. The physiotherapist will place the hypothenar region of his hand on the spinous processes of the symptomatic lumbar spine levels and waited a few seconds without no glide will be performed. Sham SNAGs practice consisted of 3 sets of 6 repetitions and a 60-second rest period was given between the sets.
Study: NCT02800395

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Malnutrition screening and perioperative nutritional support
Description: * Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines~* Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)~* Implementation of an adapted nutritional support based on ESPEN Guidelines
Study: NCT01303614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine-Prilocaine cream
Description: Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5 ml syringe without needle. Application, with a swab in gel ectocervix.
Study: NCT02651493

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: photographs
Description: computer based program to analyze photographs (computer-aided diagnosis (CAD) software)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: photographs
Description: computer based program to analyze photographs (computer-aided diagnosis (CAD) software)
Study: NCT01260961

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The volunteers will start on the 200 mg daily of the placebo and will not increase their dose during the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Docosahexanoic Acid
Description: The volunteers will start on the 200 mg daily of the DHA capsule and will not increase their dose during the study.
Study: NCT02614508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV
Study: NCT00731731

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT02417961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously every 4 weeks
Study: NCT01330199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Sampling
Description: Blood plasma, Rectal, Cervical, and Vaginal Tissues and Secretions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Sampling
Description: Blood plasma, Rectal, Cervical, and Vaginal Tissues and Secretions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Sampling
Description: Blood plasma, Rectal, Cervical, and Vaginal Tissues and Secretions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Sampling
Description: Blood plasma, Rectal, Cervical, and Vaginal Tissues and Secretions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Sampling
Description: Blood plasma, Rectal, Cervical, and Vaginal Tissues and Secretions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Sampling
Description: Blood plasma, Rectal, Cervical, and Vaginal Tissues and Secretions
Study: NCT02324699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02697838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib (850 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-based chemotherapeutic regimens
Description: Paclitaxel-based chemotherapeutic regimens including:~1. The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~2. The PF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~3. Paclitaxel 80mg/m2 d1，d8，d15，repeating the cycle every 28 days~4. other paclitaxel-based regimens
Study: NCT02874105

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group C: physiotherapy protocol with Conventional physiotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group S: physiotherapy protocol with Dynamic Humeral Centering.
Study: NCT02185547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoloft
Description: Sertraline treatment 25 mg

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ICBT
Description: Internet behavioral cognitive therapy only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT
Description: Internet behavioral cognitive therapy only
Study: NCT01663558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imiquimod

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ablative
Study: NCT04467346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ped-TMZ
Description: Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition for at least 8 hours before dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ped-TMZ
Description: Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition for at least 8 hours before dosing
Study: NCT03132662

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 3 gr/day of Omega-3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Very Low Calorie Diet
Description: 4 servings/day Optifast
Study: NCT03616964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT04467398

Intervention type: PROCEDURE
Intervention: trigeminal nerve block
Description: Trigeminal nerve or branch block using 22 gauge Quincke or Tuohy needle under fluoroscopic guidance.

Intervention type: PROCEDURE
Intervention: trigeminal nerve block
Description: Trigeminal nerve or branch block using 22 gauge Quincke or Tuohy needle under fluoroscopic guidance.
Study: NCT01097499

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OsseoPulse device (Light emitting diode technology)
Description: Patients in this group will be given the LED device and will be instructed on how and when to use it. They will receive LED treatment to the surgical site preoperatively by the surgeon for 20 minutes. Then, patients in this group will apply LED at home to the surgical site postoperatively at the day of surgery and for the following 9 postoperative days.